top of page
  • Writer's pictureSMEFG

ONLINE TALK with Prof Ron Davis: Progress and Challenges for a ME/CFS Diagnostic

Updated: Oct 14, 2021

You can find the recording of this event on this page.

Huge thanks to Ron and Janet!

 

We are thrilled to be hosting a talk and Q&A session with Prof Ron Davis on the progress and challenges for a Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) diagnostic. What a prestigious guest to celebrate the 20th anniversary of our charity!

This event is free and open to all.



Abstract

A significant portion of the Stanford Genome Technology Center’s advanced technologies are being focused on myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS), which afflicts up to an estimated approximately two million people in the United States. There is currently no biological test to diagnose ME/CFS and as a result, diagnosing ME/CFS patients is a lengthy and costly process, constituting a fundamental impediment to patient care. This lag in diagnosis also erects barriers to research, complicating patient recruitment for clinical trials of new treatments. To remedy this situation, the SGTC is pioneering several areas of research on ME/CFS in order to search for a cause and establish a diagnostic that can be rapidly disseminated.


The technologies we are developing target the biophysical properties of the cells and molecules, and therefore do not rely on introducing labels or other complex sample preparation techniques. We have successfully applied these technologies to detecting drug resistance, resolving cells and molecules in bodily fluids and tissues, and engineering advanced, multiparametric, wearable biosensors. We have begun applying these methods to understand chronic fatigue syndrome, one of the last major diseases about which almost nothing is known. We anticipate that these technological breakthroughs coupled with data integration of personal molecular profiles will play an instrumental role in the realization of personalized health regimens and disease prevention strategies.



About Ron

Ronald W. Davis, Ph.D., is Professor of Biochemistry and of Genetics at Stanford University School of Medicine, Director of the Stanford Genome Technology Center, and Director of the Chronic Fatigue Syndrome Research Center at Stanford University. Dr. Davis is a member of the National Academy of Sciences. Throughout his career he has made numerous seminal discoveries that have accelerated genetics, genomics, and bioengineering, including over 70 patented technologies that have launched numerous successful companies. His contributions have been recognized by the Gruber Genetics Prize, the Genetics Society of America Medal, the Warren Alpert Prize, and the Personalized Medicine World Conference Luminary Award. In 2013, he was named one of the 7 World’s Greatest Inventors by The Atlantic. He now is devoted to finding a cure for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

847 views0 comments

We Need Your Support Today!

Sheffield ME and Fibromyalgia Group

Address: 

The Circle

33 Rockingham Lane

Sheffield

S1 4FW

Email: info@sheffieldmegroup.co.uk

Phone: 0114 2536700

(Mon - Thurs 10.45am - 2.15pm)

Registered Charity: 1095416

Get our e-news

If you are looking to access activities, benefits advice, or the private Facebook group, please note you will need to purchase membership here

Many thanks to all our generous donors, and to our funders...

Big_Lottery_Fund_logo.png
HW_Sheffield_logo.png
ppl-neighbourhood-logo.jpg
Lloyds Bank Foundation England & Wales white bg.png
VAS Voluntary Action Sheffield logo.jpg
Sheffield Town Trust_logo_white bg.JPG
JG Graves Charitable Trust_logo.JPG
CUTLERS COMPANY CHARITABLE TRUST_logo.jfif

© 2020 Sheffield ME and Fibromyalgia Group  Registered Charity Number 1095416 |  Terms of Use  |   Privacy Policy

DISCLAIMER:
The inclusion of information of any kind on this website does not imply a recommendation or guarantee of accuracy. Nor are any views or comments necessarily those of the Group. Before embarking on anything different or new, you are advised to discuss this with your doctor.

bottom of page